S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
ASX:RCE

Recce Pharmaceuticals Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume630,087 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive RCE News and Ratings via Email

Sign-up to receive the latest news and ratings for Recce Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.64 million
Book Value
A$0.12 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Recce Pharmaceuticals (ASX:RCE) Frequently Asked Questions

What stocks does MarketBeat like better than Recce Pharmaceuticals?

Wall Street analysts have given Recce Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Recce Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Recce Pharmaceuticals' earnings last quarter?

Recce Pharmaceuticals Ltd (ASX:RCE) issued its earnings results on Wednesday, February, 27th. The company reported ($0.01) EPS for the quarter.
View Recce Pharmaceuticals' earnings history
.

Who are Recce Pharmaceuticals' key executives?

Recce Pharmaceuticals' management team includes the following people:
  • Mr. James Hamilton-Bray Graham, CEO & MD
  • Ms. Michele Keryn Dilizia, Chief Scientific Director & Exec. Director
  • Dr. Justin Ward, Principal Quality Chemist & Exec. Director
  • Mr. Arthur Kollaras, Principal Engineer & Head of Manufacturing
  • Mr. Justin Reynolds, Chief Financial Officer
  • Mr. Daniel Astudillo B.A., B.Com., M.B.A., Marketing Mang.
  • Prof. Philip Sutton, Member of Clinical Advisory Committee & Head of Helicobacter Pylori Devel. Program
  • Mr. Alistair McKeough BA, LLB, LLM, Company Sec.

What other stocks do shareholders of Recce Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Immutep (IMMP), Mavenir (MVNR), Applied Optoelectronics (AAOI), 5G Networks (5GN), Ilika (IKA), IOOF (IFL), Turtle Beach (HEAR) and First Graphene (FGR).

What is Recce Pharmaceuticals' stock symbol?

Recce Pharmaceuticals trades on the ASX under the ticker symbol "RCE."

How much money does Recce Pharmaceuticals make?

Recce Pharmaceuticals has a market capitalization of $0.00 and generates $1.64 million in revenue each year.

What is Recce Pharmaceuticals' official website?

The official website for Recce Pharmaceuticals is www.recce.com.au.

How can I contact Recce Pharmaceuticals?

The company can be reached via phone at 61 2 8075 4585.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.